Badry Bursulaya

Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors

Yong Jia, Cai‐Hong Yun, Eunyoung Park et al. · Nature · 2016 · 851 citations · Full text

Molecular Pharmacology, Medicine, Pharmacology +4

Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors

Jianming Zhang, Francisco Adrián, Wolfgang Jahnke et al. · Nature · 2010 · 590 citations

Molecular Pharmacology, Drug Target, Medicine +5

Targeting Plasmodium PI(4)K to eliminate malaria

Case W. McNamara, Chek Shik Lim, Siau Hoi Lim et al. · Nature · 2013 · 419 citations · Full text

Antiparasitic Agent, Medicine, Malaria +4

Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness

Shilpi Khare, A. S. Nagle, Agnes Biggart et al. · Nature · 2016 · 407 citations · Full text

Proteasome Inhibition, Medicinal Chemistry, Antiparasitic Agent +11

Synthesis, Structure–Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-<i>N</i>2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-<i>N</i>4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials

Thomas H. Marsilje, Wei Pei, Bei Chen et al. · Journal of Medicinal Chemistry · 2013 · 405 citations · Full text

Chemoprevention Strategy, Pharmacotherapy, Structure–activity Relationships +21